Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, June 20, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies... | June 20, 2023

Related Keywords

Richa Kumari ,James Levine ,Kiki Patel ,Prnewswire Cardiff Oncology Inc ,Gilmartin Group ,Cardiff Oncology Inc ,Nasdaq ,Taft Communications ,Cardiff Oncology ,Nasdaq Listing Rule ,Oncology Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Han ,Pune ,023 ,Cardiff ,Biotechnology ,Company ,Eleveraging ,Ilk1 ,Ncology ,Drug ,O ,Evelop ,Ovel Crdf Us14147l1089 ,